The department of Neurology is a research centre with a strong focus on patient oriented research. All staff members are involved in research. There are three main research lines: infection & inflammation, cerebrovasculair disorders, and movement disorders.
Infection & inflammation
Clinical and translational research is performed on bacterial meningitis, viral encephalitis, infections complicating stroke, sepsis associated delirium, and HIV-associated neurological complications. Projects include randomized clinical trials and prospective cohort studies, combined with genetics and experimental studies using mouse models of meningitis, sepsis, and ischemic stroke. Host and pathogen genetics in bacterial meningitis are studied in a nationwide translational cohort study. Immunodepression and preventive antibiotics after stroke are investigated in a nationwide randomized clinical study. The research on systemic infection and delirium is focussed on the interaction between cytokines, acetylcholine, and microglia. The neuromuscular research is also part of the infection & inflammation line, focussing on inflammatory diseases of nerves and muscle. For all sub-areas, promising pathways and targets for pharmaceutical intervention are explored, aiming for patient benefit.
The movement disorders group conducts research that is translational and ranges from basic research to patient care. Projects include experimental studies, genetic studies, prospective cohort studies, and clinical trials. The main lines harbour research of the treatment of Parkinson’s disease, including deep brain stimulation (DBS), and research on the early diagnosis of movement disorders with the help of neurophysiologic and combined imaging techniques with the ultimate goal to improve patient care. The group has initiated and directs several large multicenter trials that assess efficacy of DBS treatments. Part of the program is dedicated to the effects of DBS on mood, behaviour and cognition. Furthermore, the group takes part in the Dutch Parkinson’s disease research network; and initiated the randomized, delayed-start, placebo-controlled, multicentre trial to investigate whether early treatment of Parkinson’s disease with levodopa has a delayed beneficial effect.